These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 23568749

  • 1. Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet tablet containing a single excipient.
    Mcconville C, Friend DR, Clark MR, Malcolm K.
    J Pharm Sci; 2013 Jun; 102(6):1859-1868. PubMed ID: 23568749
    [Abstract] [Full Text] [Related]

  • 2. Vaginal deployment and tenofovir delivery by microbicide gels.
    Gao Y, Yuan A, Chuchuen O, Ham A, Yang KH, Katz DF.
    Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971
    [Abstract] [Full Text] [Related]

  • 3. Maximized mucoadhesion and skin permeation of anti-AIDS-loaded niosomal gels.
    Zidan AS, Habib MJ.
    J Pharm Sci; 2014 Mar; 103(3):952-64. PubMed ID: 24464823
    [Abstract] [Full Text] [Related]

  • 4. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
    Johnson TJ, Clark MR, Albright TH, Nebeker JS, Tuitupou AL, Clark JT, Fabian J, McCabe RT, Chandra N, Doncel GF, Friend DR, Kiser PF.
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6272-83. PubMed ID: 23006751
    [Abstract] [Full Text] [Related]

  • 5. Reformulated tenofovir gel for use as a dual compartment microbicide.
    Dezzutti CS, Rohan LC, Wang L, Uranker K, Shetler C, Cost M, Lynam JD, Friend D.
    J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
    Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, Nakabiito C, Hoesley C, Justman J, Soto-Torres L, Patterson K, Gomez K, Hendrix CW.
    AIDS Behav; 2013 Feb; 17(2):737-47. PubMed ID: 23065145
    [Abstract] [Full Text] [Related]

  • 8. Design and in vitro evaluation of tenofovir-loaded vaginal gels for the prevention of HIV infections.
    Timur SS, Şahin A, Aytekin E, Öztürk N, Polat KH, Tezel N, Gürsoy RN, Çalış S.
    Pharm Dev Technol; 2018 Mar; 23(3):301-310. PubMed ID: 28503983
    [Abstract] [Full Text] [Related]

  • 9. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
    Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Miya N, Mlisana K, Maarshalk S, Karim SS.
    Antivir Ther; 2013 Mar; 18(3):301-10. PubMed ID: 22914267
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
    Rosen RK, Morrow KM, Carballo-Diéguez A, Mantell JE, Hoffman S, Gai F, Maslankowski L, El-Sadr WM, Mayer KH.
    J Womens Health (Larchmt); 2008 Apr; 17(3):383-92. PubMed ID: 18328009
    [Abstract] [Full Text] [Related]

  • 12. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
    Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Mâsse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L, HPTN 050 Protocol Team.
    AIDS; 2006 Feb 28; 20(4):543-51. PubMed ID: 16470118
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
    Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, Shust G, Mesquita PM, Louissaint N, Chen J, Cohen HW, Diament EC, Lee AC, Soto-Torres L, Hendrix CW, Herold BC.
    PLoS One; 2011 Jan 25; 6(1):e16475. PubMed ID: 21283552
    [Abstract] [Full Text] [Related]

  • 17. Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
    MacQueen KM, Weaver MA, van Loggerenberg F, Succop S, Majola N, Taylor D, Karim QA, Karim SA.
    AIDS Behav; 2014 May 25; 18(5):826-32. PubMed ID: 24647763
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.